Log in

NYSE:PEN - Penumbra Stock Price, Forecast & News

$161.33
-1.87 (-1.15 %)
(As of 04/1/2020 01:22 AM ET)
Today's Range
$159.32
Now: $161.33
$167.77
50-Day Range
$124.34
MA: $169.73
$193.76
52-Week Range
$121.80
Now: $161.33
$194.93
Volume532,400 shs
Average Volume355,844 shs
Market Capitalization$5.65 billion
P/E Ratio119.50
Dividend YieldN/A
Beta0.75
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands. It also offers neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400 and Penumbra SMART Coil brands. In addition, the company provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; and detachable embolic coil systems for peripheral embolization under the RUBY Coil brand, as well as microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand. Further, it offers detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand; and aspiration-based thrombectomy systems for peripheral applications under the Indigo System brand, as well as a complementary device for use with RUBY Coil and POD for vessel occlusion under the POD Packing Coil brand. The company sells its products through direct sales organizations and distributors to hospitals in neuro and peripheral vascular markets. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Read More
Penumbra logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone510-748-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$547.41 million
Cash Flow$1.30 per share
Book Value$13.91 per share

Profitability

Net Income$48.46 million

Miscellaneous

Employees2,700
Market Cap$5.65 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive PEN News and Ratings via Email

Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter.


Penumbra (NYSE:PEN) Frequently Asked Questions

How has Penumbra's stock been impacted by COVID-19 (Coronavirus)?

Penumbra's stock was trading at $176.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PEN stock has decreased by 8.8% and is now trading at $161.33. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Penumbra?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Penumbra.

When is Penumbra's next earnings date?

Penumbra is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Penumbra.

How were Penumbra's earnings last quarter?

Penumbra Inc (NYSE:PEN) announced its quarterly earnings results on Tuesday, February, 25th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.18 by $0.04. The company had revenue of $145.26 million for the quarter, compared to analyst estimates of $141.64 million. Penumbra had a net margin of 8.85% and a return on equity of 7.72%. View Penumbra's earnings history.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $635-645 million, compared to the consensus revenue estimate of $651.96 million.

What price target have analysts set for PEN?

8 Wall Street analysts have issued 12-month price targets for Penumbra's stock. Their forecasts range from $180.00 to $200.00. On average, they anticipate Penumbra's stock price to reach $190.67 in the next twelve months. This suggests a possible upside of 18.2% from the stock's current price. View analysts' price targets for Penumbra.

Has Penumbra been receiving favorable news coverage?

News stories about PEN stock have been trending very negative this week, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Penumbra earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View the latest news aboutPenumbra.

Are investors shorting Penumbra?

Penumbra saw a decrease in short interest during the month of March. As of March 13th, there was short interest totaling 3,402,700 shares, a decrease of 13.2% from the February 27th total of 3,920,000 shares. Based on an average daily volume of 312,800 shares, the days-to-cover ratio is presently 10.9 days. Currently, 10.4% of the shares of the stock are short sold. View Penumbra's Current Options Chain.

Who are some of Penumbra's key competitors?

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Splunk (SPLK), AbbVie (ABBV), salesforce.com (CRM), Intuitive Surgical (ISRG), Adobe (ADBE), DexCom (DXCM) and Paypal (PYPL).

Who are Penumbra's key executives?

Penumbra's management team includes the following people:
  • Mr. Adam Elsesser, Co Founder, Chairman, CEO & Pres (Age 57)
  • Dr. Arani Bose, Co-Founder, Chief Innovator and Director (Age 57)
  • Mr. Sridhar N. Kosaraju, CFO and Head of Strategy (Age 41)
  • Ms. Lynn Rothman, Chief Bus. Officer and Exec. VP (Age 58)
  • Mr. Daniel Donen Davis, Chief Commercial Officer (Age 41)

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

How do I buy shares of Penumbra?

Shares of PEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $161.33.

How big of a company is Penumbra?

Penumbra has a market capitalization of $5.65 billion and generates $547.41 million in revenue each year. The company earns $48.46 million in net income (profit) each year or $0.98 on an earnings per share basis. Penumbra employs 2,700 workers across the globe. View additional information about Penumbra.

What is Penumbra's official website?

The official website for Penumbra is http://www.penumbrainc.com/.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The company can be reached via phone at 510-748-3200 or via email at inves[email protected]


MarketBeat Community Rating for Penumbra (NYSE PEN)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  689 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  915
MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe PEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel